na 931 vs retatrutide Oral quadruple receptor agonist confers weight loss with minimal GI adverse events Retatrutide—A Game Changer in Obesity
Description
Funding This work was supported by the University of Iowa NET SPORE P50CA174521 and P50CA302572, HCCC NET SPORE, HCCC Oberley, and HCCC P30 CA086862 grants
Evaluation of Out-of-Pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 RA in patients with type 2 diabetes and cardiovascular disease
Figure 1: Relative weekly search frequency for the term Ozempic using the Google Search Engine
Lean, M
[DOI] [PubMed] [Google Scholar] Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W
GLP-1s also reduce your appetite, so you end up eating less
